Compare BCBP & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | UNCY |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 145.3M |
| IPO Year | 2005 | 2021 |
| Metric | BCBP | UNCY |
|---|---|---|
| Price | $9.52 | $6.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.00 | ★ $38.00 |
| AVG Volume (30 Days) | 80.9K | ★ 506.1K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | $407.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $0.47 |
| 52 Week High | $9.87 | $7.57 |
| Indicator | BCBP | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 53.81 |
| Support Level | $7.86 | $5.95 |
| Resistance Level | N/A | $7.12 |
| Average True Range (ATR) | 0.26 | 0.41 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 77.38 | 59.50 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.